An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination

A global pandemic has resulted from the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). To control the spread of SARS-CoV-2 infection, several SARS-CoV-2 vaccines have been developed and administered in a wide ran...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mai Shimizu, Kotaro Ogaki, Ryota Nakamura, Eriko Kado, Sho Nakajima, Naohide Kurita, Masao Watanabe, Kazuo Yamashiro, Nobutaka Hattori, Takao Urabe
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	COVID-19 SARS-CoV-2 Vaccine Acute disseminated encephalomyelitis mRNA Complications Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/66cc2f356d9e4afda46d66a8b690be9a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66cc2f356d9e4afda46d66a8b690be9a
record_format	dspace
spelling	oai:doaj.org-article:66cc2f356d9e4afda46d66a8b690be9a2021-11-24T04:32:30ZAn 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination2405-650210.1016/j.ensci.2021.100381https://doaj.org/article/66cc2f356d9e4afda46d66a8b690be9a2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2405650221000745https://doaj.org/toc/2405-6502A global pandemic has resulted from the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). To control the spread of SARS-CoV-2 infection, several SARS-CoV-2 vaccines have been developed and administered in a wide range of age groups. Messenger ribonucleic acid (mRNA)-based COVID-19 vaccines are the most widely used. We present the case of an 88-year-old woman who was diagnosed with acute disseminated encephalomyelitis (ADEM) following her second mRNA COVID-19 vaccination. She was admitted to hospital with disturbed consciousness (Glasgow Coma Scale E1V1M4) and gaze-evoked nystagmus. Brain magnetic resonance imaging revealed bilateral presence of middle cerebellar peduncle sign. Following steroid pulse therapy, clinical symptoms improved. The occurrence of ADEM following COVID-19 vaccination does not question the importance of vaccination programs during the COVID-19 pandemic. COVID-19 vaccines have been administered to individuals of a wide range of ages, from children to older adults. Thus, ADEM could occur following COVID-19 vaccination at any age, although ADEM is rare in older adults.Mai ShimizuKotaro OgakiRyota NakamuraEriko KadoSho NakajimaNaohide KuritaMasao WatanabeKazuo YamashiroNobutaka HattoriTakao UrabeElsevierarticleCOVID-19SARS-CoV-2VaccineAcute disseminated encephalomyelitismRNAComplicationsNeurology. Diseases of the nervous systemRC346-429ENeNeurologicalSci, Vol 25, Iss , Pp 100381- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 SARS-CoV-2 Vaccine Acute disseminated encephalomyelitis mRNA Complications Neurology. Diseases of the nervous system RC346-429
spellingShingle	COVID-19 SARS-CoV-2 Vaccine Acute disseminated encephalomyelitis mRNA Complications Neurology. Diseases of the nervous system RC346-429 Mai Shimizu Kotaro Ogaki Ryota Nakamura Eriko Kado Sho Nakajima Naohide Kurita Masao Watanabe Kazuo Yamashiro Nobutaka Hattori Takao Urabe An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
description	A global pandemic has resulted from the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). To control the spread of SARS-CoV-2 infection, several SARS-CoV-2 vaccines have been developed and administered in a wide range of age groups. Messenger ribonucleic acid (mRNA)-based COVID-19 vaccines are the most widely used. We present the case of an 88-year-old woman who was diagnosed with acute disseminated encephalomyelitis (ADEM) following her second mRNA COVID-19 vaccination. She was admitted to hospital with disturbed consciousness (Glasgow Coma Scale E1V1M4) and gaze-evoked nystagmus. Brain magnetic resonance imaging revealed bilateral presence of middle cerebellar peduncle sign. Following steroid pulse therapy, clinical symptoms improved. The occurrence of ADEM following COVID-19 vaccination does not question the importance of vaccination programs during the COVID-19 pandemic. COVID-19 vaccines have been administered to individuals of a wide range of ages, from children to older adults. Thus, ADEM could occur following COVID-19 vaccination at any age, although ADEM is rare in older adults.
format	article
author	Mai Shimizu Kotaro Ogaki Ryota Nakamura Eriko Kado Sho Nakajima Naohide Kurita Masao Watanabe Kazuo Yamashiro Nobutaka Hattori Takao Urabe
author_facet	Mai Shimizu Kotaro Ogaki Ryota Nakamura Eriko Kado Sho Nakajima Naohide Kurita Masao Watanabe Kazuo Yamashiro Nobutaka Hattori Takao Urabe
author_sort	Mai Shimizu
title	An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
title_short	An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
title_full	An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
title_fullStr	An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
title_full_unstemmed	An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
title_sort	88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based covid-19 vaccination
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/66cc2f356d9e4afda46d66a8b690be9a
work_keys_str_mv	AT maishimizu an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT kotaroogaki an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT ryotanakamura an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT erikokado an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT shonakajima an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT naohidekurita an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT masaowatanabe an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT kazuoyamashiro an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT nobutakahattori an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT takaourabe an88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT maishimizu 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT kotaroogaki 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT ryotanakamura 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT erikokado 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT shonakajima 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT naohidekurita 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT masaowatanabe 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT kazuoyamashiro 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT nobutakahattori 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination AT takaourabe 88yearoldwomanwithacutedisseminatedencephalomyelitisfollowingmessengerribonucleicacidbasedcovid19vaccination
_version_	1718415979781816320

An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination

Ejemplares similares